WUNDERKIND
21.5.2024 15:01:26 CEST | Business Wire | Press release
Wunderkind, the leading AI-driven performance marketing solution, today announced the launch of its AI-powered Autonomous Marketing Platform and its first application, Studio, which brings self-service tools to the creative workflow for marketers and services teams.
Wunderkind’s Autonomous Marketing Platform leverages the power of artificial intelligence (AI) to streamline the entire marketing build, report and optimisation process. Through the analysis of trillions of behavioural data points, the platform uncovers valuable insights, facilitating the creation and execution of strategies that drive undeniable performance. The Wunderkind platform delivers on marketing use cases, such as making actionable data available through identity, leveraging AI to deliver omnichannel experiences, measuring insights and integrating with the broader martech ecosystem.
The Autonomous Marketing Platform is underpinned by the Wunderkind Identity Network, a proprietary Identity graph which recognises over 9 billion consumer devices, 1 billion opted-in consumer profiles and observes 2 trillion events per year. This allows Wunderkind to identify up to 50% more consumer profiles than leading email service providers (ESPs), enabling its AI-powered marketing engine to deliver significantly more personalised, 1:1 emails and text messages to drive ROI.
Studio, the First Application in the Platform Roadmap
As the critical marketing infrastructure for more than 700 brands and retailers, Wunderkind’s Studio streamlines the design process to create best-in-class brand experiences for the entire creative process. Studio provides the ability to make real-time creative edits to experiences, which is improving the time to build and launch campaigns by over 50% for Wunderkind clients. The Generative AI (Gen AI) capabilities in Studio empower marketers to quickly optimise their messaging, ensuring optimal conversions based on Wunderkind’s observation across trillions of consumer interactions.
Studio represents a watershed moment for Wunderkind, marking a significant evolution in its AI-driven product vision, which centres on providing adaptive learning and decisioning to proactively elevate marketing performance. Wunderkind’s roadmap includes additional AI-powered applications to further optimise the creation of bespoke customer experiences, robust audience development and deep analytics on engagement and revenue attribution.
This investment in the platform and its connected applications complements Wunderkind’s award-winning managed service offering, which delivers more than $5 billion in guaranteed revenue every year for brands such as Uniqlo, Sonos, Clarks and Kurt Geiger, and typically generates more than 10% of total digital revenue for clients.
“Our Autonomous Marketing Platform brings the full potential of our proprietary data and best practices to scale through AI,” Bill Ingram, CEO at Wunderkind, commented. “Studio significantly reduces the time spent on building marketing creatives and elevating outstanding performance. Wunderkind’s continued investments in AI allows us to deliver dynamic consumer experiences, which drive revenue while guiding brands through massive industry changes.”
Molly Delp, VP of eCommerce and Digital Marketing at skincare brand True Botanicals, commented: “We love Wunderkind because it's a managed service that lets us focus on our day-to-day while their professional services team delivers the engagement and eCommerce revenue lift we need. The launch of Studio brings speed and agility to our revenue strategy”.
Wunderkind will host a virtual public roadmap event on 26 June 2024, which will provide further details on its Autonomous Marketing Platform and other forthcoming applications planned to help marketers drive further enhanced performance and ROI. To register, sign up here.
Notes to editors
About Wunderkind
Wunderkind is the leading AI-driven performance marketing solution that collects consent-based, first-party data and identifies anonymous traffic for brands in order to scale hyper-personalised one-to-one messages. Brands lean on the Wunderkind Identity Network, a proprietary database recognising 9 billion devices and 1 billion opted-in consumers, observing 2 trillion digital transactions per year, to trigger the most impactful offers to their target audience at the right moment and in the right channel. This proprietary data is accessed by Wunderkind's autonomous AI engine, which integrates seamlessly into a brand's existing ESP, to boost performance across email, text and advertising channels.
Wunderkind is the only performance solution that guarantees a lift in revenue for its clients and delivers over $5 billion in directly attributable revenue annually for brands across a number of industries, often ranking as a top 3 revenue channel in clients' own analytics platforms. Brands such as Harley-Davidson, Perry Ellis and Shoe Carnival partner with Wunderkind to drive top-line revenue through its guaranteed results. To learn more, visit wunderkind.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521214381/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
